Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The MINDACT trial: the first prospective clinical validation of a genomic tool.

Molecular oncology - 1 Dec 2007

Cardoso Fatima, Piccart-Gebhart Martine, Van't Veer Laura, Rutgers Emiel

Abstract excerpt

One of the main challenges in oncology today has become to distinguish accurately between those patients who need adjuvant treatment and those who do not. This, together with the identification of the best type of therapy for the individual patient and the development of drugs targeting specific characteristics of tumour cells, are the goals of treatment tailoring or personalized medicine. The MINDACT trial...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemotherapy, Adjuvant
Share to Clinical Trials as Topic
Share to Genomics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Multicenter Studies as Topic

Share to Oligonucleotide Array Sequence Analysis

Share to Randomized Controlled Trials as Topic

Share to Reproducibility of Results

Share to Research Design

Source

Open in PubMed Open full text

Identifiers

PMID: 19383299
DOI: 10.1016/j.molonc.2007.10.004
PMCID: PMC5543876

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

The MINDACT trial: the first prospective clinical validation of a genomic tool.PMID 19383299Read ↗

<p class="MDPI12titleori1" style="mso-line-height-alt: 14.0pt;"><span style="mso-bidi-font-size: 18.0pt; mso-bidi-font-weight: bold;">MammaPrint™ Genetic Signature in the Brazilian Population, Analysis of Results and Clinical Outcomes (AGEMA-BRA) – Real World StudySemantic proximity Read ↗

Performance Characteristics of the MammaPrint ® Breast Cancer Diagnostic Gene SignatureSemantic proximity Read ↗

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.Semantic proximity Read ↗

Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancerSemantic proximity Read ↗

Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trialSemantic proximity Read ↗

Personalized neoadjuvant strategy using 70-gene assay in ER-positive/HER2- negative breast cancer to increase breast-conserving surgery rate (KBCSG016: PLATO trial)Semantic proximity Read ↗

A Nomogram for Predicting Mammaprint Results in Women with T1-3N0-1M0 Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor-2-Negative Breast CancerSemantic proximity Read ↗

Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.Semantic proximity Read ↗

Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)Semantic proximity Read ↗

AXINEO: AXIllary response to NEOadjuvant chemotherapy for breast cancer: can we predict response based on a biomarker panel?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.